{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:33:06Z","timestamp":1758943986940},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T00:00:00Z","timestamp":1032393600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Extracellular proteolytic enzymes of the urokinase\u2010type plasminogen activator (uPA) system and the family of metalloproteases play a crucial role in the matrix degradation and tissue remodelling processes characteristic of malignant disorders. The receptor for urokinase plasminogen activator (uPAR) serves to localise and intensify the action of uPA and is expressed on the surface of malignant as well as tumour stromal cells including fibroblasts. A soluble form of uPAR (suPAR) cleaved from its glycosyl\u2010phosphatidylinositol anchor is detected in plasma from healthy individuals and increased levels of suPAR have been found in advanced malignancy, suggesting that suPAR may be a marker of extensive tissue remodelling. In an attempt to clarify whether suPAR might be a marker for bone marrow tissue remodelling we measured plasma suPAR levels in a patient cohort comprising 17 with myelofibrosis (MF), 17 with polycythaemia vera (PV), 15 with essential thrombocythaemia (ET), one with a transitional myeloproliferative disorder evolving from PV and 30 controls. Compared with controls suPAR levels were significantly higher in the patients (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) (median 3.35 vs. 2.32\u2003\u00b5g\u2003L<jats:sup>\u22121<\/jats:sup>). Moreover, in subgroup analyses including patients with MF, PV, and ET, respectively, suPAR levels differed significantly with the highest levels found in patients with MF and PV (MF vs. PV vs. ET; <jats:italic>P<\/jats:italic>\u2003=\u20030.0003). When comparing suPAR levels of the individual patient subgroups with controls, only suPAR levels of PV and MF patients were significantly increased (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Sixty\u2010five percent of patients with PV and MF (22\/34) had suPAR plasma values that were above the mean +2\u2003standard deviations (SD) of controls. The concentration of suPAR was significantly correlated to plasma lactate dehydrogenase, thrombomodulin, and complex of tPA:PAI\u20101 in the patients. There was no difference between patients and controls when comparing plasma uPA levels. Increased plasma suPAR levels in patients with chronic myeloproliferative disorders may reflect increased uPAR production in the bone marrow, leading to enhanced bone marrow remodelling.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.01732.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:53:10Z","timestamp":1047408790000},"page":"43-49","source":"Crossref","is-referenced-by-count":10,"title":["Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera"],"prefix":"10.1111","volume":"69","author":[{"given":"Morten Krogh","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke","family":"Riisbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"De Nully Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,9,19]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.45.6.461"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64511-7"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_13_5_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.160.2.691","article-title":"Adenovector\u2010mediated expression of human thrombopoietin cDNA in immune\u2010compromised mice: insights into the pathophysiology of osteomyelofibrosis","volume":"160","author":"Frey BM","year":"1998","journal-title":"JImmunol"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04970.x"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1342"},{"key":"e_1_2_13_8_2","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4049\/jimmunol.153.6.2819","article-title":"Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines","volume":"153","author":"Rameshwar P","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1999.tb01534.x"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050497"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z"},{"key":"e_1_2_13_12_2","first-page":"636","article-title":"The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients","volume":"60","author":"Foekens JA","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.9.2319"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)00022-8"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08213.x"},{"key":"e_1_2_13_16_2","doi-asserted-by":"crossref","first-page":"14543","DOI":"10.1016\/S0021-9258(18)42072-8","article-title":"Purified alpha 2\u2010macroglobulin receptor\/LDL receptor\u2010related protein binds urokinase plasminogen activator inhibitor type\u20101 complex. Evidence that the alpha 2\u2010macroglobulin receptor mediates cellular degradation of urokinase receptor\u2010bound complexes","volume":"267","author":"Nykjaer A","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/102.6.835"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614558"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910620608"},{"key":"e_1_2_13_20_2","first-page":"1911","article-title":"Receptor for urokinase is present in tumor\u2010associated macrophages in ductal breast carcinoma","volume":"53","author":"Pyke C","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.150398"},{"key":"e_1_2_13_22_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V79.5.1178.1178","article-title":"Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin\u20101, and transforming growth factor\u2010beta","volume":"79","author":"Hannocks M\u2010J","year":"1992","journal-title":"Blood"},{"key":"e_1_2_13_23_2","article-title":"Measurements of soluble urokinase plasminogen activator receptor in serum","author":"Riisbro R","year":"2002","journal-title":"J Clin Ligand Assay"},{"key":"e_1_2_13_24_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/clinchem\/43.10.1868","article-title":"ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients","volume":"43","author":"Stephens RW","year":"1997","journal-title":"Clin Chem"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.869"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1994.tb01291.x"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.8.488"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02030.x"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00359.x"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10054"},{"key":"e_1_2_13_31_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_13_32_2","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the polycythemia vera study group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_13_33_2","first-page":"42","article-title":"Sensitive and specific enzyme\u2010linked immunosorbent assay for urokinase\u2010type plasminogen activator and its application to plasma from patients with breast cancer","volume":"111","author":"Gr\u00d8ndahl\u2010Hansen J","year":"1988","journal-title":"JLaboratory Clin Med"},{"key":"e_1_2_13_34_2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.V91.7.2305","article-title":"Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor\u2010urokinase complexes","volume":"91","author":"Chavakis T","year":"1998","journal-title":"Blood"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(00)00141-1"},{"key":"e_1_2_13_36_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0038-1656003","article-title":"The urokinase\u2010receptor (CD87) is expressed in cells of the megakaryoblastic lineage","volume":"77","author":"Wohn K\u2010D","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_13_37_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV\u20101, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia vera","volume":"95","author":"Temerinac S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb04904.x"},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041640214"},{"key":"e_1_2_13_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(97)90043-X"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.15.1.8679225"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80351-1"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.2.9707052"},{"key":"e_1_2_13_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041580303"},{"key":"e_1_2_13_45_2","first-page":"59","article-title":"Transforming growth factor\u2010beta stimulates urokinase expression in tumor\u2010associated macrophages of the breast","volume":"78","author":"Hildenbrand R","year":"1998","journal-title":"Laboratory Invest"},{"key":"e_1_2_13_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<236::AID-IJC12>3.0.CO;2-9"},{"key":"e_1_2_13_47_2","first-page":"111","article-title":"Localization of urokinase\u2010type plasminogen activator in stromal cells in adenocarcinoma of the colon in humans","volume":"138","author":"Gr\u00d8ndahl\u2010Hansen J","year":"1991","journal-title":"Am J Pathol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.01732.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.01732.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.01732.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:43:15Z","timestamp":1697496195000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.01732.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1034\/j.1600-0609.2002.01732.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.01732.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}